This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutEfficacySafetyDosingSupport & ResourcesPatient SupportMaterialsVideos

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 of the SmPC for how to report adverse reactions.

NGENLA — the once weekly growth hormone (GH) for children with GH deficiency1About NGENLALoading NGENLA — the once weekly growth hormone (GH) for children with GH deficiency1About NGENLALoadingFor the treatment of children and adolescents from age 3 years with growth disturbance due to insufficient secretion of growth hormone.1   EFFICACY

Access data on the efficacy of NGENLA.

View efficacy data
SAFETY

Learn more about clinical safety data of NGENLA in children with GH deficiency.

View safety data
DOSING & ADMINISTRATION

Click here for more information on NGENLA once weekly dosing and administration.

See instructions
PATIENT SUPPORT

Support for your patients throughout their treatment journey.

Explore more Loading
RESOURCES

Professional resources, materials, and videos.

Explore more Loading
Consider NGENLA for all your appropriate patients from age 3 years with paediatric growth hormone deficiency1

Ngenla▼ Prescribing Information

References:NGENLA®Summary of Product Characteristics. 

Legal Category: S1A
Further information is available upon request

PP-NGE-IRL-0015  Date of Preparation Dec 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0733. March 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024